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Background: People with HIV (PWHIV) have improved survival due to the advent of 
antiretroviral therapy. Consequently, PWHIV experience higher rates of many non-AIDS 
defining malignancies (NADM). Previous studies have shown worsened cancer-specific survival 
in PWHIV, partly due to advanced cancer stage at diagnosis. The purpose of this systematic 
review is to evaluate screening disparities for NADM among PWHIV. 
Methods: PubMed, Cochrane, EMBASE, and ClinicalTrials.gov were searched from 
January 1, 1996 through April 10, 2018 to identify any study related to screening disparities for 
NADM in PWHIV. Eligibility criteria included any study performed in a high-income country 
that compared screening for NADM by HIV status. After review of titles/abstracts, full-text 
articles, and study quality, results were included studies were synthesized. 
Results: Of 697 articles identified through searches, 9 studies met full inclusion criteria; 3 
addressed breast cancer screening, 4 addressed colorectal cancer screening, and 2 addressed 
prostate cancer screening. Five studies demonstrated that PWHIV were less likely to receive 
indicated cancer screenings compared with the general population while 3 showed that screening 
proportions were higher in PWHIV; 1 showed that screening proportions were comparable. In a 
majority of the studies, PWHIV with regular access to healthcare were more likely to undergo 
cancer screening. The studies also demonstrated that patients with poor insurance status, access 
to healthcare, education, income-level were less likely to receive cancer screening. 
Conclusions: The available evidence does not uniformly confirm that PWHIV are less 
likely to receive cancer screening. Social determinants of health were associated with receipt of 
appropriate cancer screening, suggesting that these barriers need to be addressed to improve 




The advent of antiretroviral therapy (ART) has led to decreased morbidity and mortality 
in people with HIV/AIDS (PWHIV). From 1999 to 2011, rates of all-cause death in this 
population decreased from 17.5% to 9.5%.1 As PWHIV are living longer with better-controlled 
HIV, they are experiencing higher incidence of chronic and age-related diseases, such as cancer. 
The burden of cancer in PWHIV has increased over time,2, 3 and cancer has now become a 
leading non-AIDS cause of death in the HIV population.1 
Cancer epidemiology among PWHIV has shifted since the introduction of ART.4 Over a 
ten-year time period, rates of AIDS-defining malignancies, including Kaposi sarcoma, non- 
Hodgkin lymphoma, and cervical cancer, decreased three-fold whereas rates of many non-AIDS 
defining malignancies (NADM) increased three-fold.2 Lung cancer is the most common NADM 
in PWHIV, accounting for 20% of the cancer burden.2 Of the other NADM with recommended 
screening guidelines, breast cancer constitutes 7%, prostate constitutes 6%, and colorectal cancer 
constitutes 6% of the cancer incidence in PWHIV.2 In spite of the increased prevalence of screen 
detectable cancers, little is known about utilization of cancer screening among PWHIV. 
Unfortunately, PWHIV have worse cancer survival,5 potentially due to their later stage at 
presentation, as compared to their uninfected counterparts.6 Although differences in survival 
persist even when factoring in cancer stage at diagnosis, detecting disease at a later stage leads to 
more complex treatment approaches and worse survival. Thus, utilization of age-appropriate 
cancer screening may improve outcomes for PWHIV. In this systematic review, we synthesize 
the available literature on disparities in cancer screening for NADM among PWHIV to highlight 




A comprehensive literature search was performed to identify published articles related to 
cancer screening disparities for NADM in PWHIV. PubMed, Cochrane, and EMBASE were 
searched using the following key terms: cancer/neoplasm/malignancy, screening/early detection 
of cancer, HIV/AIDS, and healthcare disparities/barriers. Unpublished studies were searched 
using ClinicalTrials.gov. The full search strategy is shown in Appendix A. The search was 
limited to adults and included English-language studies set in high-income countries published 
after January 1, 1996. This date was chosen due to ART becoming widely available in 1996. We 
defined high-income countries using the United Nation’s classification list.7 All study designs 
were included given the paucity of data on cancer screening in this population. Pediatric studies 
and studies that focused on AIDS-defining malignancies were excluded. For a more detailed 
overview of the eligibility criteria, see Appendix B. 
Two reviewers independently screened each title and abstract to determine eligibility 
using the pre-determined inclusion criteria. Articles that met possible inclusion were subjected to 
dual, independent full-text review to assess for eligibility. Discrepancies were further reviewed 
for consensus. 
For studies that met full inclusion criteria, one investigator extracted information about 
populations, screening interventions, settings, and designs, and a second investigator reviewed 
for completeness and accuracy. For interventions, the proportion of HIV and non-HIV 
participants that underwent cancer screening in each study was extracted. Studies were grouped 
for comparison according to cancer type. For all studies, the difference in proportions of 
populations (HIV and non-HIV) screened was calculated along with a 95% confidence interval 
in order to compare proportions across studies. Statistical support was received from the 
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Biostatistics and Computational Biology Core of the Duke University Center for AIDS Research 
P30AI064518. Statistical analyses were executed using SAS 9.3, Cary, NC. 
The quality of included studies was assessed using the Newcastle Ottawa Scale (NOS) 
for evaluating non-randomized studies.8 The studies were rated as good quality if they met 8-9 of 
the 9 NOS criteria, fair quality if they met 6-7 of the 9 NOS criteria, or poor quality if they met 
less than 6 NOS criteria. See Appendix C for more information regarding quality designations 





Results of Literature Review 
 
In total, 613 unique articles were identified through database searches (Figure 1). Of 
these, 31 were potentially relevant articles that were subjected to full-text review, and 9 studies 
met full eligibility criteria. Figure 1 shows exclusion reasoning at the full-text stage. Of the 9 
included studies, 3 addressed breast cancer screening, 4 addressed colorectal cancer screening, 
and 2 addressed prostate cancer screening. No studies that addressed lung cancer or other non- 
AIDS defining malignancies met our inclusion criteria. Characteristics of included studies are 
described below, grouped by cancer type. 
Breast Cancer 
 
Three studies assessed breast cancer screening among HIV-infected and uninfected 
patients (Table 1). Two studies were cross-sectional and one study used a prospective cohort 
design. All three studies were rated as good quality. One study defined breast cancer screening as 
biennial mammography starting at the age of 40.9 For the remaining two studies, breast cancer 
screening was defined as biennial mammography starting at the age of 50.10, 11 All three studies 
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designated women with mammography in the two-year timeframe surrounding the study as up- 
to-date with breast cancer screening. The studies were done in three different countries: United 
States, France, and Canada. The French study’s population was limited to those living in 
metropolitan areas while the US and Canada studies’ populations were more general. The US 
study used a wider age range (40+ years old) as compared to the other two studies (50-74/75 
years old). 
Across the three studies, results were inconsistent; differences in proportions of HIV- 
infected women screened for breast cancer compared to non-infected HIV women ranged from - 
0.13 to 0.05. In 2002, Preston-Martin et al. analyzed breast cancer screening in HIV-positive 
women who lived in the United States.9 This study included 2,059 HIV-positive women and 569 
HIV-negative women and found that a higher proportion of HIV-positive women received breast 
cancer screening (0.67 vs. 0.62, respectively; p>0.05). The difference in proportions screened 
was relatively small (0.05, 95% CI: 0.005, 0.09) (Table 2a). A second study enrolled women 
living in metropolitan France (N= 225 HIV-infected women and 661 women from the general 
population).10 This study found a lower proportion of HIV-infected women received breast 
cancer screening than the general population (0.81 vs. 0.89, respectively; p>0.05). The difference 
in proportions of women screened was -0.08 (95% CI: -0.02, -0.14). The third study analyzed 
breast cancer screening among women in Ontario, Canada.11 Among 623 HIV-positive women 
and 1,446,392 HIV-negative women, fewer HIV-positive women had breast cancer screening 
than HIV-negative women (0.50 vs. 0.63, respectively; p<0.001). The difference in proportions 
screened was -0.13 (95% CI: -0.09, -0.17). 
All three studies found factors beyond HIV-status that were associated with breast cancer 
screening. Women with insurance, medical co-morbidities, recent physician visits, receipt of 
8  
other cancer preventative care, and dental care were more likely to have up-to-date breast cancer 
screening.9-11 These studies also found factors specific to HIV women that were associated with 
decreased breast cancer screening, including low/intermediate education level, irregular 





Four studies assessed colorectal cancer screening among HIV-infected and uninfected 
patients (Table 1). Two were cohort studies and two were case-control studies. All four were 
rated as fair quality. Three studies were done in the United States and one study was done in 
Canada. Two studies were performed at VA medical centers, one was done at an outpatient 
primary care clinic, and one was done using a general medical record database. Colorectal cancer 
screening was defined as fecal occult blood test (FOBT) in the past year, flexible sigmoidoscopy 
in the past 5 years, air-contrast barium enema (ACBE) in the past 5 years, or colonoscopy in the 
past 10 years. There were two exceptions to this screening definition. Guest et al. did not include 
ACBE as a colorectal cancer screening test12 and Antoniou et al. required that all endoscopic 
tests had been done within the past 5 years.13 
Results were inconsistent across the four studies; differences in proportions of HIV- 
infected individuals screened for colorectal cancer compared to non-infected HIV individuals 
ranged from -0.26 to 0.08. The first study evaluated the proportion of HIV-positive individuals 
and matched controls who received colorectal cancer screening at an outpatient VA clinic.14 This 
study included 302 HIV-positive patients and 302 matched HIV-negative controls and found that 
HIV-positive patients had a lower proportion of receiving at least one prior screening test as 
compared with uninfected controls (0.56 vs. 0.78, respectively; p<0.001). Moreover, there was a 
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lower proportion of HIV-positive patients who were up-to-date with colorectal cancer screening 
guidelines (0.49 vs. 0.66, respectively; p<0.001; difference: -0.17, 95% CI: -0.09, -0.25) (Table 
2b). Subsequently, Iqbal et al. compared colorectal cancer screening in 114 HIV-infected and 91 
non-HIV patients.15 This study found that a lower proportion of HIV-infected patients received 
colorectal cancer screening as compared with non-HIV patients (0.41 vs. 0.67, respectively; 
p<0.001; difference: -0.26, 95% CI: -0.13, -0.39). More recently, Guest et al. included 942 
patients with HIV infection and 942 matched controls without HIV and found that the proportion 
of patients with HIV infection who received colorectal screening was similar to the proportion of 
controls without HIV (0.51 vs. 0.48, respectively; p>0.05).12 The difference in proportions was 
calculated to be 0.03 (95% CI: -0.015, 0.07). The last study analyzed colorectal cancer screening 
proportions between 1,432 HIV-positive men and 742,369 men without HIV who all received 
care in Ontario, Canada.13 This study found that HIV-positive men had higher proportion of 
colorectal cancer screening as compared to their uninfected counterparts (0.49 vs. 0.41, 
respectively; p>0.05; difference: 0.08, 95% CI: 0.05, 0.12). 
These studies also discovered additional factors that contributed to colorectal cancer 
 
screening. HIV-infected individuals with a detectable viral load, younger age, no family history 
of cancer, no co-morbidities, and <10 physician visits over 2 years were less likely to be 
screened for colorectal cancer.14, 15 
Prostate Cancer 
 
Two studies reported on prostate cancer screening rates among HIV-infected and 
uninfected patients as secondary outcomes (Table 1). Because the primary aim of these studies 
was not to assess screening itself, but instead to analyze the relatedness of low prostate cancer 
incidence to low cancer screening rates in PWHIV, these studies had limitations with their 
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sample selection and forms of measurement. One was rated as poor quality,16 while one study 
was evaluated as fair quality.16, 17 Both were cohort studies set in the United States, and defined 
up-to-date prostate cancer screening as having at least one non-diagnostic PSA test after the age 
of 40. The study populations were vastly different between the two studies; one used a low- 
income population while the other used a population with health insurance and better healthcare 
access. Neither study explored other factors beyond HIV status that were associated with prostate 
cancer screening. 
The two studies produced different results; differences in proportions of HIV-infected 
men screened for prostate cancer compared to non-infected HIV men ranged from -0.38 to 0.05. 
The first study compared longitudinal data from a cohort of 721 low-income HIV-infected 
African American men to data from 49,315 men in the general population who participated in the 
2001 Behavioral Risk Factor Surveillance System survey conducted by the Centers for Disease 
Control and Prevention.16, 18 This study found that a lower proportion of HIV-infected men 
received screening as compared with men in the general population (0.19 vs. 0.57, respectively; 
difference: -0.38, 95% CI: -0.35, -0.41) (Table 2c). More recently, Marcus et al. analyzed 
prostate cancer screening in 17,424 HIV-positive men and 182,799 HIV-negative men who were 
enrolled in Kaiser Permanente.17 This study found that a higher proportion of HIV-positive men 
received prostate cancer screening by the age of 55 as compared with HIV-negative men (0.91 





Non-AIDS Defining Cancer Screening Disparities 
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This systematic review compiled and compared studies assessing screening for NADM 
among HIV-infected and uninfected cohorts. Across the 9 included studies, there was no 
consistent difference in cancer screening rates between PWHIV and uninfected people. Instead, 
screening differed according to cancer type, education-level, insurance-status, income-level, 
presence of co-morbidities, and number of visits to healthcare providers. This suggests that HIV 
status alone may not negatively influence cancer screening. However, several other factors, such 
as low income and lack of education, which are more prevalent in the United States HIV-infected 
population could explain the underutilization of cancer screening. 
This review also identified gaps in the available literature. While many studies have 
analyzed screening for AIDS-defining malignancies in this population, particularly cervical 
cancer, there was a scarcity of data on screening for NADM.19-23 One significant gap in the 
literature was the absence of studies that focused on lung cancer screening in the HIV/AIDS 
population. This is concerning because lung cancer is among the most common cancers in 
PWHIV; PWHIV are more likely to smoke, less likely to receive lung cancer treatment, and have 
higher lung cancer-specific mortality compared with the general population.24, 25 Although non- 
AIDS defining malignancies have increased in prevalence in PWHIV over the past 20 years, 
research on NADM screening in this population is limited. Future studies should investigate if 
the current cancer screening recommendations aimed at the general population are adequate for 
the HIV-infected population and if HIV specialists, who often serve as primary care providers 
for PWHIV, are offering cancer screening at appropriate intervals. 
Overall, disparate results for screening rates may reflect issues related to setting, with 
differing access to care and established screening guidelines, and study population. One potential 
explanation for differing breast cancer screening proportions in the studies is that they were all 
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performed in different countries. The French study had much higher percentages of both HIV 
and non-HIV women undergoing breast cancer screening as compared to the United States and 
Canada. In France, breast cancer screening is fully paid for by public health insurance, with 
reminders sent to women aged 50-74 years. This system has been associated with high rates of 
cancer screening, and may partly account for the differing degrees of breast cancer screening 
between France, the United States, and Canada.26 Study setting and population also likely 
contributed to differing colorectal cancer screening findings. The studies done by Reinhold et al. 
and Guest et al. were both performed at VA medical centers.12, 14 The results from these studies 
may overestimate screening rates due to universal health coverage and high compliance with 
colorectal cancer screening in VA clinics.29 Iqbal et al. included a small population sample size 
in their study, which led to decreased power.15 Additionally, Antoniou et al. could not distinguish 
between coding for diagnostic and screening endoscopic tests, thus the results from this study are 
likely an overestimation of colorectal cancer screening rates. Finally, for the prostate cancer 
screening studies, one was conducted with a small cohort of low-income males in a single US 
city and the other used individuals with access to primary care services through Kaiser 
Permanente.17 Thus, the discrepant screening results are likely related to the study populations 
having markedly different access to care. 
Reasons for Cancer Screening Disparities 
 
The literature from this review found that although HIV does not appear to drive 
disparities in cancer screening for NADM, several sociodemographic factors contribute to the 
ability to receive cancer screening. Low educational background and low-income level were 
associated with decreased cancer screening in PWHIV.10, 11 These barriers are identical to those 
identified by Lambert et al.’s review that looked at barriers to cervical cancer screening in 
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women with HIV.22 Thus, social determinants of health play a major role in the receipt of cancer 
screening in HIV-infected individuals and contribute to cancer care disparities. Additionally, the 
studies found that the presence of health insurance and increased contact with the healthcare 
system were associated with increased cancer screening receipt. Because PWHIV are more 
likely to be uninsured or underinsured but also have a higher number of annual visits as part of 
routine HIV care, this association has both a positive and a negative effect on PWHIV.27, 28 
Individuals with HIV who are able to attend regular appointments with their infectious disease 
physician or primary care provider may be more likely to remain up-to-date with their cancer 
screening, in some instances even more so than the general population due to this increased 
healthcare contact. However, for PWHIV with low socioeconomic status and no insurance, the 
lack of healthcare accessibility worsens their likelihood of receiving cancer screening. 
Consequently, improvements in insurance and access to primary care for PWHIV are needed to 
increase utilization of high-quality preventive services. 
Another explanation that could account for the decreased cancer screening in PWHIV is 
poor patient compliance despite physician recommendations for screening. Past studies have 
found that patients with HIV are more likely to have adherence challenges because of 
“forgetting”, they do not have time, they view non-HIV/AIDS related disease as low priority,  
and they have enhanced anxiety toward medical procedures.30, 31 Additionally, a qualitative study 
that analyzed cervical cancer screening barriers found that HIV-infected women had lower 
awareness, limited transportation, and concern over the pap smear procedure that prevented them 
from obtaining recommended cervical cancer screening.32 Thus, patient challenges and fears 
regarding cancer screening should be addressed by physicians and further investigated in future 
studies. 
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Finally, the presence of cancer screening disparities observed in some studies in the 
HIV/AIDS population also raises concern over the transitioning physician roles for these 
patients. As infectious disease specialists are increasingly assuming the role of the primary care 
providers for PWHIV, there is added concern over appropriate administration of preventative 
services, including cancer screening.33 Of the two studies performed in VA medical centers in 
this review, one study population received primary care solely through their infectious disease 
physicians14 and the other study population received primary care through both infectious disease 
physicians and primary care providers.12 The former had a significantly lower colorectal cancer 
screening proportion in the HIV population compared to the non-HIV population while the latter 
had comparable screening proportions in the HIV and non-HIV populations. This suggests that 
delivery of primary care services by an infectious disease specialist may lead to reduced 
screening rates. This hypothesis has not yet been studied in the published literature, however 
literature from other fields suggests that HIV specialists may focus on HIV control to the 
detriment of other routine health screening services such as blood pressure control or lipid 
monitoring. Additional research should focus on optimal screening strategies for PWHIV, as 




The literature base used for this review has some limitations. First, direct comparison of 
data was difficult due to the heterogeneity of study populations and study designs used across the 
relevant publications. Additionally, some studies had cross-sectional designs, which are inferior 
to the prospective studies used in this review due to the inability to determine causal 
relationships. Finally, measurement strategy within the studies differed. Some studies used 
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medical record review, while others used self-reported measures and surveys. This may have 
caused varied reliability of data between the studies. Second, direct comparison of data was 
difficult due to the heterogeneity of study populations and study designs used across the relevant 
publications. 
This review has potential limitations. The search strategy may have missed relevant 
articles, however the systematic approach and review by two independent reviewers minimized 
this risk. Additionally, studies from low- and middle-income countries, where the burden of HIV 
is higher than in high-income countries, were excluded. This was done to maximize homogeneity 
within study groups and enhance applicability to the HIV population in the United States. 
Finally, in order to assess disparities, studies that analyzed an HIV/AIDS population alone 
without an uninfected comparator group were excluded, thus we may have lost some data about 
barriers in cancer screening for HIV/AIDS patients. 
CONCLUSION 
 
This review synthesized findings about non-AIDS-defining malignancy screening trends 
in people with HIV/AIDS in order to investigate disparities and enhance cancer care in this 
vulnerable population. Although we found inconsistencies about the impact of HIV on cancer 
screening rates in the published literature, we consistently found that several sociodemographic 
factors disproportionally affecting the U.S. HIV-infected population do affect cancer screening. 
These factors include insurance-status, income-level, education-level, as well as access to and 
amount of contact with the healthcare system. Additionally, patient preferences and physician 
factors may contribute to underutilization of cancer screening services. As HIV/AIDS patients 
are living longer due to improved antiretroviral medications, they are experiencing a rapidly 
increasing burden of cancer. Patients living with HIV and cancer have worse cancer outcomes 
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compared with the general population, in part because of their advanced stage at diagnosis. 
Improvements in cancer screening are urgently needed to provide this population with high 
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Abbreviations: HIV= Human Immunodeficiency Virus, US= United States, FOBT= Fecal occult 
blood test, ACBE= Air-contrast barium enema, PSA= Prostate Specific Antigen 
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Cochrane Library: 409 
EMBASE: 148 
ClinicalTrials.gov: 0 
Combined search results 
(n=697) 
84 duplicates removed 
613 articles screened on 
basis of title and abstract 
582 excluded: 
19 ineligible population 
359 ineligible intervention 
90 ineligible comparator 
102 ineligible outcome 
12 ineligible setting 
31 full-text articles 
assessed for eligibility 
22 excluded: 
5 ineligible intervention 
11 ineligible comparator 
6 ineligible outcome 





Appendix A: Search terms used for the (a) PubMed, (b) Cochrane, and (c) EMBASE databases. 
 
(a) PubMed Search: 
Search # Terms Results 
#1 ("Neoplasms"[Mesh] OR Neoplasia[tiab] OR 
Neoplasias[tiab] OR Neoplasm[tiab] OR 
Neoplasms[tiab] OR Tumors[tiab] OR 
Tumours[tiab] OR Tumor[tiab] OR 
Tumour[tiab] OR Cancer[tiab] OR 
Cancers[tiab] OR Malignant[tiab] OR 
Malignancy[tiab] OR Malignancies[tiab]) 
3,802,236 
#2 (Screen[tiab] OR Screening[tiab] OR “Cancer 
Screening”[Mesh] OR "Early Detection of 
Cancer"[Mesh] OR Mammogram[tiab] OR 
Colonoscopy[tiab] OR PSA[tiab]) 
589,429 
#3 ("HIV Infections"[Mesh] OR HIV[tiab] OR 
"Human Immunodeficiency Virus"[tiab] OR 
"Acquired Immune Deficiency Syndrome"[tiab] 
OR "Acquired Immuno Deficiency 
Syndrome"[tiab] OR "Acquired 
Immunodeficiency Syndromes"[tiab] OR 
AIDS[ti] OR AIDS[ot]) 
376,867 
#4 #1 AND #2 AND #3 2,070 
#5 #4 AND ("Healthcare Disparities"[Mesh] OR 
disparity[tiab] OR disparities[tiab] OR "Health 
Services Accessibility"[Mesh] OR equity[tiab] 
OR (barrier[tiab] OR barriers[tiab] OR) OR 
difference[tiab] OR comparison[tiab]) 
146 
#6 #5 NOT (Editorial[ptyp] OR Letter[ptyp] OR 
Case Reports[ptyp] OR Comment[ptyp]) 
145 
#7 #6 NOT (("Adolescent"[Mesh] OR 
"Child"[Mesh] OR "Infant"[Mesh]) NOT 
"Adult"[Mesh]) 
144 
#8 #7 from 01/01/1996 to present 140 
 
(b) Cochrane Search: 
Search # Terms Results 
23  
#1 MeSH: Neoplasms 64,351 
#2 Ti/ab: Neoplasia OR Neoplasias OR Neoplasm 
OR Neoplasms OR Tumors OR Tumours OR 
Tumor OR Tumour OR Cancer OR Cancers OR 
Malignant OR Malignancy OR Malignancies 
141,865 
#3 #1 OR #2 148,304 
#4 MeSH: Early Detection of Cancer 1,115 
#5 Ti/ab: Screen OR Screening OR Mammogram 
OR Colonoscopy OR PSA 
43,258 
#6 #4 OR #5 43,404 
#7 MeSH: HIV 3,050 
#8 Ti/ab: HIV OR Human Immunodeficiency 
Virus OR Acquired Immune Deficiency 
Syndrome OR Acquired Immuno Deficiency 
Syndrome OR Acquired Immunodeficiency 
Syndromes OR AIDS 
27,230 
#9 #7 OR #8 27,230 
#10 #3 AND #6 AND #9 413 
#11 #10 from 01/01/1996 to present 409 
 
(c) EMBASE Search: 
Search # Terms Results 
#1 (‘Neoplasms’/exp OR (Neoplasia OR 
Neoplasias OR Neoplasm OR Neoplasms OR 
Tumors OR Tumours OR Tumor OR Tumour 
OR Cancer OR Cancers OR Malignant OR 
Malignancy OR Malignancies)) 
5,649,963 
24  
#2 (Screen OR Screening OR Mammogram OR 
Colonoscopy OR PSA):ab,ti OR ‘Cancer 
Screening’/exp OR ‘Early Detection of 
Cancer’/exp 
813,505 
#3 #1 AND #2 275,284 
#4 (‘HIV Infections’/exp OR (HIV OR ‘Human 
Immunodeficiency Virus’ OR ‘Acquired 
Immune Deficiency Syndrome’ OR ‘Acquired 
Immuno Deficiency Syndrome’ OR ‘Acquired 
Immunodeficiency Syndromes’ OR 
AIDS):ab,ti) 
516,865 
#5 #3 AND #4 5,572 
#6 #5 AND ('healthcare disparities'/exp OR 
barrier:ab,ti OR barriers:ab,ti OR disparity:ab,ti 
OR equity:ab,ti OR accessibility:ab,ti OR 
difference:ab,ti OR comparison:ab,ti) 
275 
#7 #6 NOT (‘Adolescent’/exp OR ‘Child’/exp OR 
‘Infant’/exp NOT ‘Adult’/exp) 
268 




Appendix B: Eligibility criteria. 
 
Eligibility Criteria 
• Population: Adult patients (>18 years old) diagnosed with HIV/AIDS 
• Intervention: Screening for non-AIDS defining malignancies 
• Comparator: Adults (>18 years old) who have not been diagnosed with 
HIV/AIDS 
• Outcomes: Cancer screening rates and/or disparities 
• Timing: Studies published after January 1, 1996 




1 Defined from the United Nation’s classification list7 
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2015 
Cohort Study + 
  




Shiels, 2010 Cohort Study - 
  
- + + 
  




First Author, Year 
Comparability Outcome 
Study controls 
for main factor 









Adequacy of follow-up 
Breast Cancer Preston-Martin, 2002 - + +   + + 
 Tron, 2017 + + + - +   
 Kendall, 2017 + + + + +   
Colorectal 
Cancer 
Reinhold, 2005 + + 
     
 Iqbal, 2010 - + +   - - 
 Guest, 2014 + +      
 Antoniou, 2015 - + +   - - 
Prostate Cancer Shiels, 2010 - - +   + + 
 Marcus, 2014 - + +   + + 
 
  
First Author, Year 
Exposure Number of Criteria Fulfilled 
Ascertainment of exposure Same method of ascertainment Non-response rate  
Breast Cancer Preston-Martin, 2002    8 
 Tron, 2017    8 
 Kendall, 2017    9 
Colorectal 
Cancer 
Reinhold, 2005 + + + 7 
 Iqbal, 2010    6 
 Guest, 2014 + + + 7 
 Antoniou, 2015    6 
Prostate Cancer Shiels, 2010    5 
 Marcus, 2014    7 
 
(+) indicates study met criterion 
(-) indicates study did not meet criterion 







1. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV 
from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384: 241-248. 
2. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the 
United States. J Natl Cancer Inst. 2011;103: 753-762. 
3. Seaberg EC, Wiley D, Martinez-Maza O, et al. Cancer incidence in the multicenter AIDS 
Cohort Study before and during the HAART era: 1984 to 2007. Cancer. 2010;116: 5507-5516. 
4. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non- 
AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer. 
2005;104: 1505-1511. 
5. Coghill AE, Shiels MS, Suneja G, Engels EA. Elevated Cancer-Specific Mortality Among 
HIV-Infected Patients in the United States. J Clin Oncol. 2015;33: 2376-2383. 
6. Shiels MS, Copeland G, Goodman MT, et al. Cancer stage at diagnosis in patients infected 
with the human immunodeficiency virus and transplant recipients. Cancer. 2015;121: 2063-2071. 
7. World Economic Situation and Prospects 2018. New York, NY, USA, 2018. 
 
8. Wells GS, B.; O’connell, D.; Peterson, J.;Welch, V.; Losos, M.; Tugwell, P. The Newcastle- 
Ottawa Scale (Nos) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 
Ottawa Hospital Research Institute. 2000. 
9. Preston-Martin S, Kirstein LM, Pogoda JM, et al. Use of mammographic screening by HIV- 
infected women in the Women's Interagency HIV Study (WIHS). Prev Med. 2002;34: 386-392. 
10. Tron L, Lert F, Spire B, Dray-Spira R. Levels and determinants of breast and cervical cancer 
screening uptake in HIV-infected women compared with the general population in France. HIV 
Med. 2017;18: 181-195. 
28  
11. Kendall CE, Walmsley S, Lau C, et al. A cross-sectional population-based study of breast 
cancer screening among women with HIV in Ontario, Canada. CMAJ Open. 2017;5: E673-e681. 
12. Guest JL, Rentsch CT, Rimland D. Comparison of colorectal cancer screening and diagnoses 
in HIV-positive and HIV-negative veterans. AIDS Care. 2014;26: 1490-1493. 
13. Antoniou T, Jembere N, Saskin R, Kopp A, Glazier RH. A population-based study of the 
extent of colorectal cancer screening in men with HIV. BMC Health Serv Res. 2015;15: 51. 
14. Reinhold JP, Moon M, Tenner CT, Poles MA, Bini EJ. Colorectal cancer screening in HIV- 
infected patients 50 years of age and older: missed opportunities for prevention. Am J 
Gastroenterol. 2005;100: 1805-1812. 
15. Iqbal S, Browne-McDonald V, Cerulli MA. Recent trends for colorectal cancer screening in 
HIV-infected patients. Dig Dis Sci. 2010;55: 761-766. 
16. Shiels MS, Goedert JJ, Moore RD, Platz EA, Engels EA. Reduced Risk of Prostate Cancer in 
 
U.S. Men with AIDS. Cancer Epidemiol Biomarkers Prev. 2010;19: 2910-2915. 
 
17. Marcus JL, Chao CR, Leyden WA, et al. Prostate cancer incidence and prostate-specific 
antigen testing among HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr. 
2014;66: 495-502. 
18. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in 
the United States: does practice reflect the evidence? Jama. 2003;289: 1414-1420. 
19. Ogunwale AN, Coleman MA, Sangi-Haghpeykar H, et al. Assessment of factors impacting 
cervical cancer screening among low-income women living with HIV-AIDS. AIDS Care. 
2016;28: 491-494. 
29  
20. Williams M, Moneyham L, Kempf MC, Chamot E, Scarinci I. Structural and sociocultural 
factors associated with cervical cancer screening among HIV-infected African American women 
in Alabama. AIDS Patient Care STDS. 2015;29: 13-19. 
21. Nankya E, Wood C, Ainsworth J, Schwenk A, Waters A, Johnston V. Assessing the uptake 
of cervical screening amongst HIV-positive women attending an HIV clinic in the UK. HIV 
Med. 2015;16: 71. 
22. Lambert CC, Chandler R, McMillan S, Kromrey J, Johnson-Mallard V, Kurtyka D. Pap test 
adherence, cervical cancer perceptions, and HPV knowledge among HIV-infected women in a 
community health setting. J Assoc Nurses AIDS Care. 2015;26: 271-280. 
23. Burchell AN, Andany N, Antoniou T, et al. Pap cytology testing among HIV-positive and 
HIV-negative women in Ontario, 2008-2013: Suboptimal for cervical cancer prevention. 
Canadian Journal of Infectious Diseases and Medical Microbiology. 2015;26: 19B. 
24. Suneja G, Shiels MS, Melville SK, Williams MA, Rengan R, Engels EA. Disparities in the 
treatment and outcomes of lung cancer among HIV-infected individuals. Aids. 2013;27: 459- 
468. 
25. Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New 
Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14: 824-835. 
26. Pivot X, Rixe O, Morere JF, et al. Breast cancer screening in France: results of the EDIFICE 
survey. International Journal of Medical Sciences. 2008;5: 106-112. 
27. Goldman DP, Leibowitz AA, Joyce GF, et al. Insurance status of HIV-infected adults in the 
post-HAART era: evidence from the United States. Appl Health Econ Health Policy. 2003;2: 85- 
90. 
30  
28. Bhattacharya J, Goldman D, Sood N. The link between public and private insurance and 
HIV-related mortality. J Health Econ. 2003;22: 1105-1122. 
29. Jha AK, Perlin JB, Kizer KW, Dudley RA. Effect of the transformation of the Veterans 
Affairs Health Care System on the quality of care. N Engl J Med. 2003;348: 2218-2227. 
30. Campbell J, Young B. Use of screening colonoscopy in ambulatory HIV-infected patients. J 
Int Assoc Physicians AIDS Care (Chic). 2008;7: 286-288. 
31. Shubber Z, Mills EJ, Nachega JB, et al. Patient-Reported Barriers to Adherence to 
Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PLoS Med. 2016;13: 
e1002183. 
32. Fletcher FE, Buchberg M, Schover LR, et al. Perceptions of barriers and facilitators to 
cervical cancer screening among low-income, HIV-infected women from an integrated HIV 
clinic. AIDS Care. 2014;26: 1229-1235. 
33. Lakshmi S, Beekmann SE, Polgreen PM, Rodriguez A, Alcaide ML. HIV primary care by 
the infectious disease physician in the United States - extending the continuum of care. AIDS 
Care. 2018;30: 569-577. 
